Perceptive Advisors portfolio
Type not verifiedPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Perceptive Advisors reported a $6.4 bn portfolio of 99 companies (101 positions, counting each share class separately) to the SEC as of the end of Q2 2026. Its largest positions are PRAX, SYRE, CELC. During the quarter it opened Biogen and UnitedHealth Group.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Perceptive Advisors has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
Form 4 · 863,060 shares · trade of Aug 26 · filed Aug 27, 2026 · filing ↗
Stake reported in the company · event of Oct 5, 2026 · filed Nov 3, 2026 · filing ↗
Stake reported in the company · event of Oct 26, 2026 · filed Oct 26, 2026 · filing ↗
Stake reported in the company · event of Oct 6, 2026 · filed Oct 14, 2026 · filing ↗
Stake reported in the company · event of Sep 29, 2026 · filed Oct 1, 2026 · filing ↗
Stake reported in the company · event of Sep 16, 2026 · filed Sep 23, 2026 · filing ↗
Stake reported in the company · event of Aug 26, 2026 · filed Aug 27, 2026 · filing ↗
- 13GBlossomhill Therapeutics5.9 %
Stake reported in the company · event of Aug 7, 2026 · filed Aug 14, 2026 · filing ↗
Plus 17 more, in its EDGAR filings.
What changed this quarter
80 positions with a change (16 new, 28 added to, 28 trimmed, 8 sold); also, 5 entered through an IPO, 3 exited through an acquisition or merger. 9 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Newly listedKardiganKARD3.0% of the portfolio
- Newly listedAvalyn PharmaAVLN1.4% of the portfolio
It started trading this quarter: it appears in a 13F for the first time. The filing does not say whether the manager already held it before the listing, so it is not counted as a purchase.
- Ascendis Pharma A/S−24%fewer sharesReduced6.9% → 4.8%
- Relay Therapeutics+45%more sharesIncreased1.9% → 4.1%
- Tango Therapeutics+318%more sharesIncreased0.3% → 1.6%
- Biogen+0.9 ppof portfolioNew— → 0.9%
- Revolution Medicines+104%more sharesIncreased0.5% → 1.5%
- UnitedHealth Group+0.8 ppof portfolioNew— → 0.8%
- Spyre Therapeutics+14%more sharesIncreased3.8% → 6.0%
- Dyne Therapeutics−42%fewer sharesReduced1.7% → 0.9%
- Abivax−77%fewer sharesReduced0.7% → 0.2%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Praxis Precision MedicinesPRAX10.6%
- Spyre TherapeuticsSYRE6.0%
- CelcuityCELC5.2%
- Ascendis Pharma A/SASND4.8%
- Rhythm PharmaceuticalsRYTM4.5%
- Roivant SciencesROIV4.5%
- Relay TherapeuticsRLAY4.1%
- Travere TherapeuticsTVTX3.3%
- KardiganKARD3.0%
- Nuvalent3.0%
- Edgewise TherapeuticsEWTX2.8%
- Apogee Therapeutics2.7%
- Amylyx PharmaceuticalsAMLX2.3%
- MeiraGTx HoldingsMGTX2.3%
- Oruka TherapeuticsORKA2.0%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 101
Q2 2026: 49%
Q2 2026: 12.5%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
13F filings with amendments or confidential positions
- 13F Q1 2026 ↗filed May 15, 2026Amendment of May 29, 2026 (replaces the original) ↗
- 13F Q1 2025 ↗filed May 15, 2025Amendment of Aug 6, 2025 (replaces the original) ↗
Declared options (7)
Besides stocks, Perceptive Advisors declared 6 puts (they gain if the stock falls) and 1 call (they gain if it rises) with a notional of $221M. The 13F reports the value of the underlying shares, not the premium paid, so these figures look large and are not added to the portfolio. Nor does it say whether the option is bought or written, or its strike or expiry: it may be a hedge.
- PUTModernaMRNA$70.0M
- PUTState Street SPDR S&P Biotech ETFXBInew this quarter$47.5M
- PUTEyePointEYPTnew this quarter$28.6M
- CALLCapricor TherapeuticsCAPRnew this quarter$24.1M
- PUTSELLAS Life Sciences GroupSLSnew this quarter$22.1M
- PUTNewAmsterdam PharmaNAMSnew this quarter$16.9M
- PUTCapricor TherapeuticsCAPRnew this quarter$12.0M
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Type not verified: we have not assigned a type because we found no document that is enough to tell. Most 13F filers are in this situation: we only review in depth those that meet the portfolio criteria.
Not counted as a concentrated manager: its portfolio is not within 5 to 100 positions. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- Ruane, Cunniff & GoldfarbInvestment firm · $6.4 bn
- Reaves W HInvestment firm · $6.6 bn
- Alpha Wave GlobalInvestment firm · $6.2 bn
- Longview Partners (Guernsey)Investment firm · $6.2 bn
- Soros Fund Management$6.1 bn
- Disciplined Growth InvestorsInvestment firm · $5.9 bn